Barriers and Facilitators to Engagement With a Weight Management Intervention in Asian Patients With Overweight or Obesity: A Systematic Review

Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long‐term mortality in acute myocardial infarction

“…21,35,36 Targeting common biological mechanisms of metabolic dysregulations that underlie hepatic steatosis and coronary artery disease, through exercise and dietary modifications, can help establish the unified goal in addressing liver and cardiovascular-related endpoints. 63,64 In fact, the plethora of upcoming trials in the search for the first US Food and Drug Administration-approved medication for non-alcoholic steatohepatitis has led to promising data that describe the combined improvement in both liver and cardiovascular-related outcomes with the use of drugs such as peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists and sodiumglucose co-transporter-2 inhibitors. 17,[65][66][67][68] Several studies on peroxisome proliferator-activated receptor agonists and sodium-glucose cotransporter-2 inhibitors have also shown the reduction in liver biochemistry and/or hepatic fat content or fibrosis, as well as the improvement in cardiovascular outcomes, such as high-density lipoprotein levels and triglycerides, which are independent of diabetes status.…”

“…Targeting common biological mechanisms of metabolic dysregulations that underlie hepatic steatosis and coronary artery disease, through exercise and dietary modifications, can help establish the unified goal in addressing liver and cardiovascular‐related endpoints 63,64 . In fact, the plethora of upcoming trials in the search for the first US Food and Drug Administration‐approved medication for non‐alcoholic steatohepatitis has led to promising data that describe the combined improvement in both liver and cardiovascular‐related outcomes with the use of drugs such as peroxisome proliferator‐activated receptor agonists, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors 17,65‐68 .…”

General Public’s knowledge, awareness, and perception of Cardiometabolic diseases: data from a Singapore study population

“…Those with MFs had lower knowledge scores on all cardiometabolic domains when compared to their counterparts without MFs. Although it is plausible that the higher baseline knowledge of cardiometabolic diseases has equipped individuals to take preemptive measures early to mitigate the risk of cardiometabolic diseases ( 53 ), this still raises concerns over the discrepancy in the knowledge gap in those living with cardiometabolic diseases ( 54 , 55 ). Despite the increased perceived susceptibility of those with MFs, it is concerning that this did not appear to translate into self-reported actions taken to improve metabolic health.…”

“…Moving forward, the findings from this study can be used to tailor appropriate healthcare policies, especially towards the Singaporean population. In the 21st century, with an increasingly obesogenic environment, coupled with poor nutrition and sedentarism ( 54 , 79 , 80 ), the burden of cardiometabolic diseases is expected to rise further in Asia ( 81 , 82 ). It is therefore paramount that early action is taken to mitigate this public health burden.…”

The experience of living with obesity for adults in Asian countries: A scoping review of qualitative studies

“…10 Similarly, another systematic review of Asian patients with overweight and obesity also found that sociocultural norms were a barrier to eating behavior and engagement with weight management interventions. 46 This substantial impact of social norms and perceptions could be related to collectivism in Asian culture. Individualism-collectivism is a cultural dimension 18 of the way people view themselves in relation to others.…”